Mirae Asset Healthcare Fund vs UTI - Healthcare Fund
Mirae Asset Healthcare Fund and UTI - Healthcare Fund are both Pharma & Healthcare Funds. As of 6 Nov 2026 (Direct plan, Growth option): 3-year CAGR +24.82% vs +24.40%, 5-year CAGR +17.33% vs +17.01%, volatility 15.16% vs 15.09%, maximum drawdown −19.98% vs −27.10%. Their portfolios overlap by 51.4% (19 stocks held by both).
Showing the Direct plan, Growth option. Portfolio, sector and market-cap figures are the same for every plan and option of a fund.
Key facts
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Fund house | Mirae Asset Mutual Fund | UTI Mutual Fund |
| Compared as | Pharma & Healthcare Funds | Pharma & Healthcare Funds |
| NAV | ₹53.8740 | ₹390.6233 |
| NAV date | 6 Nov 2026 | 6 Nov 2026 |
| Launched (first NAV) | 3 Jul 2018 | 2 Jan 2013 |
| Track record | 8.3 yrs | 13.8 yrs |
| Fund size (AUM) | ₹3,494 Cr | — |
| Securities held | 30 | 44 |
| Portfolio as of | 30 Sep 2026 | 30 Sep 2026 |
| Fund page | Full record → | Full record → |
Returns
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| 1 month | +5.54% | +3.21% |
| 3 months | +4.19% | +1.26% |
| 6 months | +14.25% | +13.06% |
| 1 year | +24.35% | +18.81% |
| 3 years (CAGR) | +24.82% | +24.40% |
| 5 years (CAGR) | +17.33% | +17.01% |
| 7 years (CAGR) | +25.71% | +23.86% |
| 10 years (CAGR) | — | +15.73% |
| Since launch (CAGR) | +22.27% | +16.40% |
| SIP return (XIRR, 5 years) ⓘ | +21.75% | +21.38% |
Up to one year: absolute return. Beyond one year: CAGR. Computed from each fund's own NAV history (AMFI), measured to the latest NAV.
Calendar-year returns
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| 2026 (year to date) | +25.69% | +21.46% |
| 2025 | −1.99% | −2.18% |
| 2024 | +41.20% | +44.27% |
| 2023 | +36.06% | +39.56% |
| 2022 | −10.47% | −11.30% |
| 2021 | +28.58% | +20.35% |
Risk
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Volatility (annualised) ⓘ | 15.16% | 15.09% |
| Downside volatility ⓘ | 8.74% | 8.87% |
| Sharpe ratio ⓘ | 1.21 | 1.19 |
| Sortino ratio ⓘ | 2.10 | 2.02 |
| Maximum drawdown ⓘ | −19.98% | −27.10% |
| Recovery from that fall | 1 months | 1 months |
| Current fall from peak | 0.00% | −1.11% |
| Rolling 1-year return: worst | −11.12% | −18.18% |
| Rolling 1-year return: median | +19.09% | +12.82% |
| Rolling 1-year return: best | +93.05% | +86.35% |
| Share of 1-year periods with a loss | 17.84% | 30.85% |
Against each fund's benchmark
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Beta ⓘ | 0.69 | 0.76 |
| Alpha (Jensen's, annualised) ⓘ | +13.42% | +12.77% |
| R² ⓘ | 46.28 | 54.87 |
| Upside capture | 112.85% | 118.59% |
| Downside capture | 42.42% | 54.68% |
| Tracking error | 12.63% | 11.40% |
| Information ratio | 1.10 | 1.18 |
| Treynor ratio | 25.39 | 22.64 |
Portfolio
Asset mix
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Equity | 99.98% | 94.15% |
| Cash & equivalents | 0.02% | 5.87% |
| Mutual Fund Units | 0.01% | 0.00% |
Market-cap split (share of fund assets)
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Large Cap | 34.99% | 18.21% |
| Mid Cap | 42.11% | 33.64% |
| Small Cap | 19.51% | 39.16% |
| Unclassified | 3.37% | 3.14% |
Concentration
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Top 10 holdings | 58.41% | 43.48% |
| Effective number of stocks ⓘ | 20 | 33 |
| Securities held | 30 | 44 |
Portfolio overlap: 51.4%
19 companies are held by both funds; by weight, 51.4% of the two portfolios is the same. That is a high overlap: holding both adds little diversification beyond holding one.
| Held by both | Mirae Asset Healthcare | UTI - Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 10.15% | 7.62% |
| Divi's Laboratories Limited | 9.79% | 6.15% |
| Dr. Reddy's Laboratories Limited | 4.84% | 5.24% |
| Alkem Laboratories Limited | 3.76% | 3.70% |
| Apollo Hospitals Enterprise Limited | 5.62% | 3.03% |
| IPCA Laboratories Limited | 3.39% | 2.81% |
| Gland Pharma Limited | 2.69% | 4.06% |
| Max Healthcare Institute Limited | 2.35% | 2.80% |
| Lupin Limited | 2.27% | 2.89% |
| Glenmark Pharmaceuticals Limited | 4.78% | 2.12% |
| Aurobindo Pharma Limited | 3.78% | 2.07% |
| Fortis Healthcare Limited | 2.94% | 2.02% |
| Aster DM Quality Care Limited | 3.33% | 1.76% |
| Dr. Lal Path Labs Limited | 2.90% | 1.67% |
| Biocon Ltd. | 2.01% | 1.62% |
Top 10 holdings
Mirae Asset Healthcare
- Sun Pharmaceutical Industries Limited10.15%
- Divi's Laboratories Limited9.79%
- Torrent Pharmaceuticals Limited6.80%
- Apollo Hospitals Enterprise Limited5.62%
- Laurus Labs Limited5.51%
- Dr. Reddy's Laboratories Limited4.84%
- Glenmark Pharmaceuticals Limited4.78%
- Aurobindo Pharma Limited3.78%
- Alkem Laboratories Limited3.76%
- IPCA Laboratories Limited3.39%
UTI - Healthcare
- Sun Pharmaceutical Industries Limited7.62%
- Divi's Laboratories Limited6.15%
- Dr. Reddy's Laboratories Limited5.24%
- Ajanta Pharma Limited4.81%
- Gland Pharma Limited4.06%
- Alkem Laboratories Limited3.70%
- Apollo Hospitals Enterprise Limited3.03%
- Caplin Point Laboratories Limited3.02%
- Global Health Limited2.96%
- Lupin Limited2.89%
Sector exposure
| Mirae Asset Healthcare | UTI - Healthcare | |
|---|---|---|
| Pharmaceuticals & Biotechnology | 75.78% | 68.48% |
| Healthcare Services | 20.52% | 23.31% |
| Chemicals & Petrochemicals | 1.90% | 1.28% |
| Healthcare Equipment & Supplies | 1.77% | 1.08% |
| Unclassified | 0.01% | 0.00% |
Questions people ask
What is the difference between Mirae Asset Healthcare and UTI - Healthcare returns?
As of 6 Nov 2026, Direct plan Growth option: 1-year return +24.35% vs +18.81%; 3-year CAGR +24.82% vs +24.40%; 5-year CAGR +17.33% vs +17.01%; 10-year CAGR — vs +15.73%. Past returns do not indicate future returns.
How do Mirae Asset Healthcare and UTI - Healthcare compare on risk?
Volatility (36 monthly returns, annualised) 15.16% vs 15.09%; Sharpe ratio 1.21 vs 1.19; Sortino ratio 2.10 vs 2.02; maximum drawdown −19.98% vs −27.10%; beta 0.69 vs 0.76.
How much do Mirae Asset Healthcare and UTI - Healthcare overlap?
By weight, 51.4% of the two portfolios is invested in the same companies; 19 stocks are held by both, the largest shared positions being Sun Pharmaceutical Industries Limited, Divi's Laboratories Limited, Dr. Reddy's Laboratories Limited. Based on the portfolios disclosed for Sep 2026 and Sep 2026.
What is the large, mid and small cap split of Mirae Asset Healthcare and UTI - Healthcare?
Mirae Asset Healthcare: large cap 35.0%, mid cap 42.1%, small cap 19.5%. UTI - Healthcare: large cap 18.2%, mid cap 33.6%, small cap 39.2% (share of the fund's assets, from its latest disclosed portfolio).
Is this a recommendation to choose one of these funds?
No. This page places the published figures of both funds side by side. It does not rank, rate or recommend either fund; which one suits an investor depends on their goals, horizon and risk tolerance.
More comparisons
Mirae Asset Healthcare vs
- Mirae Asset Healthcare vs Bajaj Finserv Healthcare
- Mirae Asset Healthcare vs ITI Pharma and Healthcare
- Mirae Asset Healthcare vs Tata India Pharma & Healthcare
- Mirae Asset Healthcare vs HDFC Pharma and Healthcare
- Mirae Asset Healthcare vs PGIM India Healthcare
- Mirae Asset Healthcare vs Bandhan Healthcare
All Pharma & Healthcare Funds comparisons → · Compare up to six funds yourself → · Every fund in this category → · All comparisons →
Sources: NAV from AMFI; returns, risk and ratios computed by MF Analyser from each fund's NAV history (risk on 36 monthly returns, risk-free rate 6.5%); benchmark ratios against each fund's benchmark total-return index; portfolios from each fund house's monthly disclosure. Returns and ratios as of 6 Nov 2026. IDCW options show no return or risk figures because payouts reduce the NAV and AMFI's file carries no payout history to add back. This page compares published figures only — it does not rank, rate or recommend either fund. Past performance does not indicate future returns; mutual fund investments are subject to market risks.